% | $
Quotes you view appear here for quick access.

PDL BioPharma, Inc. Message Board

  • yamandolio yamandolio Jun 11, 2014 11:10 AM Flag

    PDLI rank

    Zacks rank is HOLD ??????

    MSN Money rank is STRONG BUY (9)
    TheStreet rank is BUY
    VectorVest Rank is BUY
    BarChart indicators: 80% BUY for Short Term, 100% BUY for Long Term

    "Expected revenues will be above consensus - second quarter royalty revenues will increase on a sequential basis".

    PDLI has got the lowest P/E and PEG of the Industry.


    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Perhaps you might consider why these are so low. The company's principal revenue source will expire in less than two years at this point and will not be easily replaced. Certainly not on the basis of the acquisitions made so far. This means that earnings and the dividend will be sharply lower in the not too distant future.

      I would actually be quite interested in hearing a bull story on this stock that does not rely on ratios that are essentially meaningless at this point given the unique nature of the company's assets and business.

      • 1 Reply to pharmarobot
      • Normally very low P/E and PEG means undervaluated stock and great forcasted growing..
        Do you mean that MSN, TheStreet, Vector Vest, ... are completely wrong in their ranking?
        Recentley there is an interesting article released by Seeking Alpha with the following summary:
        •PDL is focused on the quality of the income-generating assets and potential returns on investment.
        •It has deployed $700 million to-date for its strategic initiative of bringing in new income-generating assets from the healthcare sector; recently acquired $150 million worth of secured notes from kaleo.
        •Yielding at 6.79%, the company offers one of the most attractive dividends in the industry.
        •Considerable growth in revenues, earnings and free cash flows over the last few years.
        •Trading at 5.1x its past earnings and 4.3x its forward earnings, PDL is significantly undervalued compared to the broader market and its industry peers.

3.15+0.02(+0.64%)4:00 PMEDT